GNBT: Penny stock, speculative biotech to considerUp sharply today on news (see below)
Looks to me like forming a likely inverse head and shoulders pattern.
Often with H&S there is a fairly symmetrical time difference between and shoulders and the top or bottom as we have here (horizontal arrows).
Like all biotechnology stocks this could be a bust or very volatile.
"Generex Signs a Memorandum of Understanding with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia."
Biotech
Photocure $PHO.OL testing breakout from 200 and 50 moving avgIn july analysts predicted up to 100% upside in $PHO stock.
Still significant amount of short positions reported.
Merck a strong value with strong technicals and upcoming newsI've been holding Merck since its big dip to $76 back in June. At the time I set a price target of $82:
However, I didn't sell at $82 and have continued to hold the stock due to strong fundamentals, technicals, news, and sentiment. Merck has positive earnings and sales growth, with PEG ratio of 1.7 and PSG ratio of 2.3. It has a nice dividend yield at 2.9%, a rarity for a stock with such strong growth. Analysts rate it highly, with an average score of 80.25/100 from S&P Global and an Equity Starmine Summary Score of 8.5/10. With a put/call ratio of 0.41, sentiment on Merck is stronger than on most of the other stocks I watch. It's got a good ESG score and a long history of beating analyst estimates. Plus it's poised to benefit from some hype around its antiviral drug intended to fight Covid-19 that starts clinical trials in September.
In technical terms, Merck recently broke out of a triangle, got a couple bullish moving average crosses, and today broke out above its recent trading range. If Merck oscillates down to its moving averages, I may use that as an opportunity to add to my position. I think the stock still has plenty of upside, especially when the clinical trial headlines start to hit.
Krystal Biotech - good entryThese are my thoughts on KRYS. They are meant to give you an idea, not trading advice.
This chart comes together like lego. Just don't step on it. Target around 80$. Could take a few months.
Dips below 40$ are my buying opportunities. Not saying it can't go lower.
Please be careful, as the market never gives you certainties, only probabilities!
ALWAYS REMEMBER THIS WHEN YOU TRADE
INO is sitting right at support. Great entry w/ 50% upsideINO is sitting right at support. Excellent entry point with at least 50% upside min in the short term.
My target is 24.36 --- let's do this!!!
Nordic Nanovector about to have a golden cross 50/200 SMANordic Nanovector stock has been consolidating upon positive news about FDA Fast Track Status for Betalutin and amended patient eligibility criteria in the PARADIGME clinical trial, and looks set to draw a golden cross for the first time since the pre ASH rally of 2018.
Entrys should be made with keen eyes on risk management, but it is nice to see some good sentiment after a challenging period for the company.
[NVAX] Novavax: Preliminary studies produce promising resultsPreliminary studies on coronavirus vaccines have produced promising results.
I'm still a believer in their technology. Check out my previous NVAX posts and/or the first one. They have a promising technology that could revolutionize the vaccine industry. We (humanity) are already very behind in how we produce vaccines AKA using chicken eggs. So Novavax will hopefully pave the way for vaccines going forward.
Things to watch even after COVID-19:
- NanoFlu™
- ResVax™
- Recombinant Nanoparticle Vaccine Technology
- Matrix-M™ Adjuvant Technolog
TL;DR - To the moon and (probably) back lol
*Note: This is pure speculation and my own opinion*
NY Times: www.nytimes.com
CNBC: www.cnbc.com
GENE: Last Breakout was Crazy, High Volume Pop?GENE is one of those stocks that had support pickup for volume which lead to a really big breakout. The selloff was as bad, given many people getting excited can leave just as quick. I'm not sure I would consider it far enough evidence yet for market manipulation. That being said, even with lots of the resistance it has been receiving, I think it has potential for a positive retest. I would rate this as mid risk, but think that bullish correlations can push this past the $7 price point quite soon. That being said, please do your own due diligence. Invest at your own risk. Everything I say is on an opinion based basis.
What to expect on ER?Well seems like we continue the sell off of the Brazil news that I didn't sell. So what news is there to push it higher? Well if ER repeats the same pattern we can suspect them beating EPS and and Beating Revenue.
News
-Earnings this wednesday, a week early
-They are hitting their road map this year
www.inspiremd.com
-Atm the FDA IDE is awaiting its pr, yet questions on their recent tweet suggesting it got approved
twitter.com
-The filed for some 8-ks on a past offering that happen over two years ago. These changed the pricing of these investors to .49-.50. Heres some links to the offering it refers too and to a definetion to prospectus supplement.
www.globenewswire.com
prospectus supplement definition: the link looks funny so just google the definition
Now TA
-We been in a downward trend, yet the volume has been low. The average volume ranges from 2.5-over 4million, yet the past week its been dropping and Friday we didn't even hit a million. The only thing I could find is a low volume downward trend article titled "Low Volume Pullback" Again we going back to the FDA IDE news that many common investors suspect the news to already be dropped. Now I'm no expert on how this process works, so I'm just waiting till ER update.
www.investopedia.com
-MACD looks like its gonna turn over, but is neutral on that it is possible for a pretty big move this week in either direction.
-RSI is trending downward suggesting its becoming oversold and we could go bullish, yes it's not super oversold yet.
-I put in a new trade zone that we could just go sideways till earnings from .4499-.4594
Other notes
-I did some DD on the current CEO and notice over 2 years he produces returns for a company from when he gets hired till he leaves. If you can hold for another year and 2/3months you could see a price target of .9023 or a pt of 1.2293. This data is from his recent jobs at ticker ITAMAR and IART, which he produced returns at rougly round 4-44% as he worked for them.
-According to Fintel: on 06/09/2020 Lind Global Macro Fund LP acquired just over 3.9million shares and L1 Capital Global Opportunities Master Fund, Ltd acquired over 650k shares on 06/19/2020
fintel.io
Final thoughts
I'll hold my position, but till earnings. I'll be neutral on the buy half, yet long term you could make 100%-170% return in the next year and 3 months with the CEO past performance. They have hit the Brazil market and is growing in the US. You could see massive market cap growth.
Long MITO IdeaMITO does look good here. Volume is up this week considerably, the stock is trading above its supporting moving averages. The MACD crossed up and above the zero line. The 200sma would be a 60% gain if it makes it there.
Easy money here. Long $QLGNKeeping the great winning streak ratio alive.
CEO is great here - knows about value. I quote from his shareholders letter:
"...we believe our plans will help build significant shareholder value..." This means HI GUYS, BUY MY STOCK (lol)
These guys have the FASTEST COVID antibody test kit on the market (10 minutes vs Becton Dickinson's 15 minute kit) - it is currently SELLING and shortly we will see the FDA EUA PR.
In addition to all of this, company just closed a great offering for 8M at 5.25 - so the chart and that round is essentially backing you here. Kicker warrants are priced WAY out of the money so no dilution there.
All the main weekly oscillators SCREAM buy now - so this one is easy. Ride the wave and if there are some hiccups you add on dips, this chart is also NOTORIOUS for epic multibagger runs.
Long for the swing! Strong buy NOW
Have been following this and just a thoughtevery gap up pump on IBIO retraces back to 0.786 level. Today it touched the 0.786 level at around $4 after its last pump. Assuming similar pattern to form, the stock price will stabilize around the mid 4 waiting for another leg up. Also, this ticker is long overdue for a PR. the RSI has cooled down significantly from its run from 2.5 and still in the bullish area.
Why I am Long on $MMEDFRight now one of the stocks that have my attention, (partly because of Kevin O'Leary) and the rest of its history is Mind Medicine (MindMed Inc.) They are one of the first companies finding a way to neutralize LSD while working on a DMT based therapy drug. Also, the market cap and entry is low. This is one of those stocks where you need to dig deep into the pitch deck and look at competition, market opportunities, and entry price. Right now as a biotech company, it is one of my favorite low priced biotech stocks, and as a long hold in somebody's portfolio, I don't think the risk aversion is too high. That being said, everything I say is on an opinion based basis. Please proceed with caution and invest at your own risk. Do your own due diligence.
$ACOR can rise in the next daysContextual immersion trading strategy idea.
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States.
The demand for shares of the company looks higher than the supply.
This and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $0,86;
stop-loss — $0,81.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Biogen trend line to watchBiogen today reported a huge earning beat, but disappointing guidance for the rest of the year. When you crunch the numbers, the midpoint of Biogen's guidance range for 2H 2020 came in slightly below Street consensus for both earnings and revenues.
Biogen has a reasonable, but not great valuation, with forward PEG of 3.78 and forward PSG of 1.27. It's currently in the lower half (26th percentile) of its three-year valuation range in terms of forward P/S and forward P/E. Biogen pays no dividend, and as a result the stock is more volatile than a dividend-paying stock would be.
Sentiment on Biogen improved quite a bit today. There have been no analyst upgrades yet, but options traders moved from net-bearish to net-bullish positioning for the short term, and from net-bearish to net-neutral positioning for the long term.
We're coming up on the strong season for pharmaceutical stocks in August. Biogen has only one phase 2 clinical trial result due in the second half of 2020 for its multiple sclerosis drug, but there are five results due in the first half of 2021, including a phase 3. These could prove to be major catalysts for the stock over the next year.
For the near term, watch for a possible trend line break as a sign that the stock will move higher.
NSPR just getting started?Now buying my 3000 shares than seeing it pump to .61 (highest RH showed), was just luck with getting the news about Brazil approval NSPR product, yet looking at the chart begs to wonder is it over?
News
-CGuard got approval to be used in Brazil. I will post a DD at the end of this for NSPR, yet the consumer market of CGuard in Brazil can be up too 213 million citizens. The DD also suggest NSPR is looking for partners to China to distribute CGuard next.
-NSPR is looking for FDA IDE approval that it had to resubmit testing in May. If it gets approved it will get clinical trial testing to be able to be sold in the USA, which it already has approval for in Europe. It already has positive feedback from its test it submitted.
-Voting coming up to add more shares (double current shares). This is negative, yet with the price of a share atm I really don't think it will past, since they raised money already in early June.
-Insiders have be buying shares up to 4 million, which gives answers to the weird volume after the dump.
-Low float: tbh no clue what this means or what I'm looking at since I don't trade on what is low float. But alot of people say this stock volume should be above dollar with all the positive news.
TA
-Again volume is beyond head scratching, which reading the DD it makes since with 4million shares being bought up from CEO, Co, and other institutions.
-RSI is dead center
-MACD shows more momentum to the upside. Only thing that could affect it if tech stocks sell off again or a negative catalyst such as shares increase.
-now for the support and resitance lines short term and long term: support can be at the .50, .4922, and .4594. After that maybe new lows or a bear trap.
-Resistance is at .61/.5764, than next a bounce to $.7493-$.6491, $.9750, $1.1275, than all i got this a pump to $3.0811 (500%). One alysise has a $2 target, yet I don't see any activity since from $1.1275-$3.0811 was just a straight dump.
Final thoughts
I'll hold my 3k shares, since positive catalyist out number the negative one coming up. This company will have zero effect on its US and China relation, since its HQ is in Israel. With years of downside there is speculation what the overall outcome of this company, since it has been 15 years and its still around. I say its a hold and a buy between these ranges with .45 being buy, yet hold if it dips under that price.
DD
www.reddit.com
ABBV buy the dip ahead of pharma seasonAbbvie's volume has slackened somewhat after its recent triangle breakout, and it has broken its steep upward trendline. We may see a small correction late this month as Abbvie pulls back toward triangle top. However, if healthcare and pharmaceutical sector earnings continue to deliver this month (as they have so far), then Abbvie should get some buying volume along with the rest of the sector.
And then in August, a period of seasonal pharmaceutical strength begins. In The Stock Traders' Almanac, Jeffrey Hirsch makes an extensive study of seasonal stock market performance by sectors. His third-best-performing seasonal trade by average 10-year return (16.8%) is to go long biotech from early August to early March. I believe that's because this is the busy season for FDA drug application reviews.
The pharma sector does have an unusual level of political risk this year. Democrats have traditionally been hard on the pharma sector, and they look poised this year for a sweep. If the polls remain strongly blue, then we might see pharma underperform this year.
That said, I think a lot of the political risk is already priced in. Whereas most of the stocks I look at are at the very top of their 3-year valuation range in terms of forward earnings and sales, pharmaceutical companies like Abbvie and Merck are trading in the bottom quartile of their 3-year valuation range. With forward PEG ratio around 2, forward PSG ratio around 0.5, and a whopping 5% dividend, Abbvie looks really attractively valued. I've been doing a lot of deal-hunting lately, and this is one of the only stocks I've seen with both a strong growth story and a valuation I really like. The analysts and options traders like it too; Abbvie has a 9.9/10 Equity Starmine Summary Score, and near-dated options positions are heavily skewed toward calls.
$FIXX can rise in the next daysContextual immersion trading strategy idea.
Homology Medicines, Inc., a genetic medicine company, focuses on transforming the lives of patients suffering from rare genetic diseases.
The demand for shares of the company looks higher than the supply.
This and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $16,45;
stop-loss — $15,75.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
$CTIC can rise in the next daysContextual immersion trading strategy idea.
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers.
The share prose rose after the company had announced enrollment of first patient in the COVID-19 PRE-VENT phase 3 clinical trial.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $1,38;
stop-loss — $1,25.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Biotech Channel Held 7/21/2020This is XBI at the 4 hour view. It seems that my biotech channel was a success. XBI tried to gap above the top of the channel. However, whenever the price goes above the long-term channel, it tends to get hammered right back in.
This may provide some safer short opportunities under these conditions.
1) XBI is at the top or above the top of the channel.
2) VIX is about found support.
3) After the hype of some vaccine news.
